Shu Chen, Ph.D.
Dr. Shu Chen provides strategic patent counseling services to clients ranging from individual inventors, start-ups, research institutes, to Fortune 500 companies. She manages portfolios of patents and patent applications, helps clients develop strategies for building patent portfolios, helps clients identify patentable inventions, and prepares and prosecutes patent applications, both in the United States and internationally. Shu has helped clients navigate the changes enacted in the America Invents Act (AIA). Her current practice covers a wide range of computer-related technologies. Shu has substantial patent experience in distributed system architectures, Internet and client-server systems, search engines, cloud architectures and applications, anti-virus and data encryption techniques, telecommunications, medical devices, automobiles and mechanical devices.
Prior to joining Bass, Berry & Sims, Shu was a patent agent at a prestigious international IP boutique firm and a general practice law firm in downtown D.C. Before working in the legal industry, Shu served as a research assistant at Tufts University’s Millimeter and Submillimeter Waves Laboratory, working on free-space broad band dielectric measurement of solid materials.
Memberships
Institute of Electrical and Electronics Engineers (IEEE)
Representative Experience
-
Read More
Representation of Gen Cap America, Inc., a private equity firm focused on lower middle market buyouts, on its acquisition of Lab Products, LLC and Hartford Systems, LLC (together, “Lab Products”) from Avidity Science, LLC. Lab Products is a leading manufacturer providing an extensive line of laboratory research animal housing and care equipment. This transaction marks Gen Cap America’s fourteenth acquisition from its seventh fund.
-
Lead Counsel to POINT Biopharma Inc. in its SPAC Business Combination with Research Alliance Corp. IRead More
Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management. Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.
-
Read More
Representation of Triple Tree Capital Partners and Vestar Capital Partners in the merger of their respective portfolio companies, The Emily Program and Veritas Collaborative.
-
Read More
-
Read More
Representation of Beat the Bomb, a growth stage immersive gaming company, on fund-raising; intellectual property protection, including patent prosecution and patent counseling; and overall legal and business strategy.
-
Read More
Represented NN, Inc. in its sale of the Precision Bearing Components Group to Tsubaki Nakashima Co. for $388 million